Sodium Valproate – Kodiac biolabs

Plain-language summaryIntrigue 71 / 100

Sodium valproate (Depakote, in the divalproex form) is a deceptively simple molecule (a branched fatty acid) that turned out to do an extraordinary number of useful things in the brain: block voltage-gated sodium channels, raise GABA levels by inhibiting GABA transaminase, block T-type calcium channels, and inhibit histone deacetylases. Originally noticed in 1962 as a bioactive compound while serving as a solvent in pharmacology screening, it was approved by the FDA in 1978 and remains a first-line anticonvulsant for generalized seizures, one of the two best mood stabilizers in bipolar disorder, and a workhorse for migraine prevention. It is highly teratogenic (causes severe birth defects) and women of childbearing potential should generally avoid it. Liver toxicity, pancreatitis, and weight gain are notable. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

50/100

A mature broad-spectrum anticonvulsant with strong evidence but minimal frontier research value today

Honestly, sodium valproate is one of the clearest examples of a compound where the evidence score and the novelty score pull in completely opposite directions. It was discovered accidentally in 1962 while serving as a solvent during pharmacological screening in Lyon, approved by the FDA in 1978, and has since generated more replicated clinical data than most compounds in this library combined. That evidence quality counts for something. It just doesn’t make it an interesting research target right now.

The mechanism is genuinely multifactorial, and thats worth acknowledging. GABA transaminase inhibition, voltage-gated sodium channel blockade, T-type calcium channel modulation, and histone deacetylase inhibition all operate simultaneously in a way that’s unusual for a simple branched-chain fatty acid. The HDAC angle is actually why valproate still shows up in serious research programs at all. It’s one of the only clinically approved HDAC inhibitors with decades of human pharmacokinetic and pharmacodynamic data behind it, which gives it a specific translational utility that purely preclinical tools don’t replicate. Researchers studying VPA’s epigenetic effects in glioblastoma combination regimens, ALS neuroprotection, or neuronal reprogramming protocols have a concrete reason to reach for it specifically.

But here’s the thing: if you’re running a precise HDAC inhibitor probe program, you’re probably using vorinostat, romidepsin, or a class-selective tool like entinostat, not valproate. The selectivity profile isn’t favorable for clean mechanistic dissection across HDAC subtypes. And if you’re studying anticonvulsant pharmacology, levetiracetam and lacosamide have displaced it as the more technically interesting targets in most contemporary programs. Valproate shows up in combination studies or as a reference standard, not as the primary object of investigation.

The teratogenicity history is also a real practical constraint. The regulatory environment around valproate and fetal exposure has become increasingly restrictive, particularly in Europe, and that context follows the compound into research discussions even where it’s technically irrelevant. The hepatotoxicity and hyperammonemia signals add to the handling picture.

What we like: the reference standard status is real and not nothing. Translational signal is strong almost by definition for an approved drug with three approved indications. The HDAC-in-CNS-disease literature generates actual publications in serious journals, and any bench program in neuroepigenetics should know this compound’s profile well.

What we don’t like: there’s very little left to discover. The mechanism is well-mapped. The clinical profile is settled. The research community studying this compound isn’t growing, and the novel angles that do exist are better pursued with more selective modern tools. Solid reference compound. Not a frontier target.

Novelty: 18
Mechanism promise: 42
In-category differentiation: 38
Evidence quality: 82
Translational signal: 78
Research bench value: 65

Rationale Valproate scores high on evidence and translational signal because it’s an approved drug with decades of replicated clinical data across multiple indications, but novelty is near-floor for a compound discovered in 1962 and approved in 1978. The HDAC inhibition angle is the only thing that keeps mechanism and bench-value from bottoming out, and even that story has been partially superseded by more selective HDACi tools.

Branched-chain fatty acid anticonvulsant / mood stabilizer

A simple branched-chain fatty acid with broad anticonvulsant activity and mood-stabilizing efficacy in bipolar disorder.

Abstract

Sodium valproate (sodium 2-propylpentanoate; CAS 1069-66-5; molecular formula C8H15NaO2; molecular weight 166.20) is a branched-chain fatty acid anticonvulsant first characterized as bioactive in 1962 (incidentally, while serving as a solvent in pharmacological screening at Lyon). Approved by the FDA in 1978 (Depakote, the divalproex sodium delayed-release form). Mechanism is multifactorial: GABA transaminase inhibition increases brain GABA; sodium channel blockade reduces neuronal hyperexcitability; T-type calcium channel inhibition supports anti-absence activity; histone deacetylase (HDAC) inhibition modifies gene expression with neuroprotective and possibly disease-modifying implications in bipolar disorder. Plasma half-life is 9 to 16 hours; metabolism is via beta-oxidation, omega-oxidation, and glucuronidation. Approved indications include all major seizure types (partial, generalized tonic-clonic, absence, myoclonic), bipolar I disorder mania, and migraine prophylaxis. The principal limitation is teratogenicity (neural tube defects, cognitive deficits in offspring) requiring strict avoidance in pregnancy and women of childbearing age. Hepatotoxicity, pancreatitis, and hyperammonemia are recognized adverse events. Used as the canonical broad-spectrum anticonvulsant and HDAC inhibitor reference.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-242Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.